Q-omics provides the consensus-scored ZNF385B profile across patient tissues and cancer cell-line models. ZNF385B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, ZNF385B is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, ZNF385B RNA expression shows 21,537 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BRCA, LUAD, and LSCC as cancer lineages where ZNF385B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF385B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF385B survival associations across molecular data types. ZNF385B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF385B RNA expression–survival associations across cancer types. High ZNF385B expression shows unfavorable associations in BLCA, but favorable associations in BRCA, KIRP, ACC, MESO and KIRC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for ZNF385B RNA expression.
This table summarizes ZNF385B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF385B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF385B shows lower tumor expression in LUAD, STAD, KIRC, BLCA, THCA and LUSC. The LUAD box plot shows higher ZNF385B RNA expression in normal versus tumor tissue (log2 FC = −2.727, t-test p < 0.001).
This table shows molecular features associated with ZNF385B in patient tissues and cancer cell lines. In patient samples, ZNF385B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF385B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
